Background: In Southeastern Europe, similar to other postsocialist regions on the continent, injection drug users (IDU) are exposed to a high risk of blood-borne infections. In this paper, we report the prevalence of HIV, hepatitis C (HCV) and hepatitis B (HBV) among IDUs in Montenegro. We also examine the risk factors associated with HCV diagnosis. Methods: In 2008, 322 IDUs in Montenegro participated in a respondent-driven sampling survey. Blood specimens were collected and tested for HIV, HCV and HBV. Behavioral data were collected with self-administered questionnaires. Results: In comparison to 2005, HCV prevalence had increased from an estimated 22 to 53.7%. Only one HIV and no HBV cases were detected. Anti-HCV positivity was associated with the region of origin, income, sharing injection equipment and frequency of injecting drugs. Conclusion: The increasing HCV prevalence among IDUs in Montenegro calls for increased and better designed programs to prevent its further spread and a potential HIV outbreak.

Keywords:
Hepatitis C virus, Respondent-driven sampling, Southeastern Europe, Injection drug users
1.
Aceijas C, Stimson GV, Hickman M, Rhodes T: Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004;18:2295–2303.
2.
Hamers FF, Downs AM: HIV in central and eastern Europe. Lancet 2003;361:1035–1044.
3.
Kelly JA, Amirkhanian YA: The newest epidemic: a review of HIV/AIDS in central and eastern Europe. Int J STD AIDS 2003;14:361–371.
4.
Rhodes T, Simic M: Transition and the HIV risk environment. BMJ 2005;331:220–223.
5.
Cohen J: Late for the epidemic: HIV/AIDS in eastern Europe. Science 2010;329:160–164.
6.
Kruglov YV, Kobyshcha YV, Salyuk T, Varetska O, Shakarishvili A, Saldanha VP: The most severe HIV epidemic in Europe: Ukraine’s national HIV prevalence estimates for 2007. Sex Transm Infect 2008;84:37–41.
7.
Platt L, Bobrova N, Rhodes T, Uusküla A, Parry JV, Rüütel K, Talu A, Abel K, Rajaleid K, Judd A: High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS 2006;20:2120–2123.
8.
Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, Renton A, Bobrova N, McDonald T, Parry JV: Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006;101:252–266.
9.
Shapatava E, Nelson KE, Tsertsvadze T, del Rio C: Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006;82:35–38.
10.
Djurić D: The economic development of Montenegro; in Bieber F (ed): Montenegro in Transition: Problems of Identity and Statehood. Baden-Baden, Nomos Verlagsgesellschaft, 2003, pp 139–158.
11.
Judd A, Rhodes T, Johnston LG, Platt L, Andjelkovic V, Simić D, Mugosa B, Simic M, Zerjav S, Parry RP, Parry JV: Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro. BMC Infect Dis 2009;9:14.
12.
Heckathorn DD: Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997;44:174–199.
13.
Heckathorn DD: Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Social Problems 2002;49:11–34.
14.
Heckathorn DD: Extensions of respondent-driven sampling: analyzing continuous variables and controlling for differential recruitment. Sociol Methodol 2007;37:151–207.
15.
Rácz J, Gyarmathy VA, Neaigus A, Ujhelyi E: Injecting equipment sharing and perception of HIV and hepatitis risk among injecting drug users in Budapest. AIDS Care 2007;19:59–66.
16.
Longshore D, Stein JA, Conner BT: Psychosocial antecedents of injection risk reduction: a multivariate analysis. AIDS Educ Prev 2004;16:353–366.
17.
Cazin I, Pristaš I, Kolarić B: Knowledge and attitudes of physicians about HIV/AIDS in primary health care practice – a pilot study in the city of Zagreb and the Zagreb county; in Gjenero-Margan I, Kolarić B (eds.): Second Generation of Surveillance in HIV Infection and AIDS in the Republic of Croatia, 2003–2006. Zagreb, Croatian National Institute of Public Health, 2006, pp 34–56.
18.
Aceijas C, Rhodes T: Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18:352–358.
19.
Richardson L, Sherman SG, Kerr T: Employment amongst people who use drugs: a new arena for research and intervention? Int J Drug Policy 2012;23:3–5.
20.
Folch C, Casabona J, Brugal MT, Majó X, Esteve A, Meroño M, Gonzalez V, REDAN Study Group: Sexually transmitted infections and sexual practices among injecting drug users in harm reduction centers in Catalonia. Eur Addict Res 2011;17:271–278.
21.
Miller CL, Johnston C, Spittal PM, Li K, Laliberté N, Montaner JSG, Schechter MT: Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737–742.
22.
Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D: Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000;14:717–726.
23.
Rhodes T, Treloar C: The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction 2008;103:1593–1603.
24.
Sarang A, Rhodes T, Sheon N, Page K: Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse 2010;45:813–864.
25.
Maher L, Dixon D: Policing and public health: law enforcement and harm minimization in a street-level drug market. Br J Criminol 1999;39:488–512.
26.
Bourgois P, Prince B, Moss A: The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Hum Organ 2004;63:253–264.
27.
Paquette D, Bryant J, de Wit J: Respondent-driven sampling and the recruitment of people with small injecting networks. AIDS Behav 2012;16:890–899.
28.
Haasen C, Verthein U, Eiroa-Orosa FJ, Schäfer I, Reimer J: Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial. Eur Addict Res 2010;16:124–130.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.